Virogenics, Inc.
San Diego, CA Doing business as Virogenics
- UEI
- UFJ8JM4CXU22
- CAGE
- 476X3
- Primary NAICS
- 238990 All Other Specialty Trade Contractors
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- NAICS codes registered in SAM.gov
- SAM.gov registration date
- Physical address
- 4050 Sorrento Valley Blvd, San Diego, CA 92121, USA
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Paving the way to phase 2 trials of CMS121 for alzheimer's disease - nearly all of the many therapeutic drug… | National Institute on Aging | $2,432,649 | |
| Long-term, non-clinical toxicology for advancing CMS121 to phase 2 trials for ad - abstract our goal is to advance… | National Institute on Aging | $6,097,277 | |
| Phase 1 clinical trial of CMS121, a novel therapeutic candidate for alzheimer's disease - abstract this application… | National Institute on Aging | $13,572,523 | |
| Modulation of the innate immune response by fisetin derivatives for the treatment of ad | National Institute of Allergy and Infectious Diseases | $2,911,623 | |
| Modulation of the innate immune response by fisetin derivatives for the treatment of ad | National Institute of Allergy and Infectious Diseases | $1,499,999 |
About Virogenics, Inc.
Virogenics, Inc. is a for-profit biotechnology company located in San Diego, California, focused on developing innovative therapeutic approaches for neurodegenerative diseases, with a particular emphasis on Alzheimer's disease (AD) drug development. The company appears to specialize in pharmaceutical research and development, specifically targeting novel drug candidates that address complex neurological conditions through unique mechanisms of action. Through federal grant awards, Virogenics, Inc. primarily engages with the National Institute on Aging (NIA) to advance cutting-edge medical research and develop potential breakthrough treatments for age-related cognitive disorders.
The company has been actively pursuing the development of CMS121, a small molecule drug candidate designed to treat Alzheimer's disease, through a series of federally funded research grants. These grants, totaling over $5.6 million, have supported critical research stages including a first-in-human Phase 1 clinical trial, long-term non-clinical toxicology studies, and preparatory work for potential Phase 2 clinical trials. The research focuses on developing a disease-modifying drug that addresses cognitive impairment by targeting lipid metabolism and mitochondrial function, which differs from existing Alzheimer's treatments. The grants have funded specific activities such as 6-month rat and 9-month dog toxicology studies, development of a tablet formulation of CMS121, and comprehensive clinical trial protocols, all aimed at advancing a novel therapeutic approach for treating mild to moderate Alzheimer's disease. Collaborating with scientific partners like the Salk Institute, Virogenics, Inc. has leveraged these federal awards to progress its innovative drug development research through rigorous scientific investigation and clinical testing.
Quick answers
What is Virogenics, Inc.'s UEI?
Virogenics, Inc.'s Unique Entity ID (UEI) in SAM.gov is UFJ8JM4CXU22.
What is Virogenics, Inc.'s CAGE code?
Virogenics, Inc.'s CAGE code is 476X3.
What is Virogenics, Inc.'s primary NAICS code?
Virogenics, Inc.'s primary NAICS code is 238990 (All Other Specialty Trade Contractors).
Where is Virogenics, Inc. located?
Virogenics, Inc.'s physical address in SAM.gov is 4050 Sorrento Valley Blvd, San Diego, CA 92121, USA.
Is Virogenics, Inc. registered in SAM.gov?
Yes. Virogenics, Inc.'s SAM.gov registration is active through January 19, 2027.
What is Virogenics, Inc.'s most recent federal award?
Virogenics, Inc.'s most recent federal grant award is Paving the way to phase 2 trials of CMS121 for alzheimer's disease - nearly all of the many therapeutic drug… (R44AG085775), from National Institute on Aging, on September 30, 2024.
On GovTribe
See Virogenics, Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors